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Abstract Objective: To compare the
management of invasive candidiasis
between infectious disease and criti-
cal care specialists. Design and set-
ting: Clinical case scenarios of inva-
sive candidiasis were presented dur-
ing interactive sessions at national
specialty meetings. Participants re-
sponded to questions using an anon-
ymous electronic voting system.
Patients and participants: Sixty-five
infectious disease and 51 critical care
physicians in Switzerland. Results:
Critical care specialists were more
likely to ask advice from a colleague
with expertise in the field of fungal
infections to treat Candida glabrata
(19.5% vs. 3.5%) and C. krusei
(36.4% vs. 3.3%) candidemia. Most
participants reported that they would
change or remove a central venous
catheter in the presence of candide-
mia, but 77.1% of critical care spe-
cialists would start concomitant anti-
fungal treatment, compared to only
50% of infectious disease specialists.
Similarly, more critical care special-
ists would start antifungal prophy-
laxis when Candida spp. are isolated
from the peritonal fluid at time of
surgery for peritonitis resulting from
bowel perforation (22.2% vs. 7.2%).
The two groups equally considered
Candida spp. as pathogens in tertiary
peritonitis, but critical care specialists
would more frequently use ampho-
tericin B than fluconazole, caspofun-
gin, or voriconazole. In mechanically
ventilated patients the isolation of 104
Candida spp. from a bronchoalveolar
lavage was considered a colonizing
organism by 94.9% of infectious
disease, compared to 46.8% of criti-
cal care specialists, with a marked
difference in the use of antifungal
agents (5.1% vs. 51%). Conclusions:
These data highlight differences be-
tween management approaches for
candidiasis in two groups of special-
ists, particularly in the reported use of
antifungals.
Keywords Antifungal treatment ·
Critical care specialists · Infectious
disease · Invasive candidiasis ·
Switzerland · Treatment survey
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Introduction
Invasive candidiasis is recognized as a leading cause of
morbidity and mortality in critically ill non-immuno-
compromised patients, with crude and attributable mor-
tality rates of more than 50% and 20%, respectively [1, 2,
3, 4, 5]. Candida spp. have been identified as a significant
pathogen in the European Study on the Prevalence of
Nosocomial Infections in Critically Ill Patients [6]. Can-
didemia represents 10-20% of candidiasis cases and is the
fourth leading organism responsible for nosocomial
bloodstream infection in the United States, preceded by
coagulase-negative staphylococci, Staphylococcus au-
reus, and enterococci [7, 8]. In Europe Candida spp.
range among the eighth to tenth leading nosocomial
bloodstream pathogens in most countries [9, 10, 11, 12].
In critically ill patients, candidemia significantly prolongs
the duration of mechanical ventilation and increases
workload, length of stay, and treatment costs [1, 4, 5].
Although never verified as effective in a prospective,
randomized, controlled trial in critically ill patients, early
preemptive antifungal therapy may improve the prognosis
of invasive candidiasis in the presence of risk factors for
infection and/or significant Candida colonization [13, 14,
15]. In addition, it corresponds to current clinical practice
among many experts, including Europeans [16, 17].
Colonization is the leading risk factor for infection in
most series in which it has been adequately explored;
Candida spp. carriage has been confirmed to be patient-
specific and to precede bloodstream or invasive infections
[18, 19]. While colonization may occur in a large pro-
portion of critically ill patients, only a minority develop
severe candidiasis [3, 20, 21, 22, 23]. In contrast to what
is currently proposed for immunocompromised hosts [16,
24], systematic recourse to antifungal prophylaxis or
preemptive therapy is not recommended for colonized
critically ill patients. In the absence of large clinical se-
ries, patients susceptible to benefit from these approaches
are difficult to identify, and current published recom-
mendations are mostly derived from consensus confer-
ences and expert opinion [25, 26, 27, 28, 29]. Accord-
ingly, the clinical management of invasive candidiasis
may differ among specialists.
The main objective of this study was to compare the
management of invasive candidiasis between infectious
disease and critical care specialists in Switzerland. We
observed notable differences in the use of antifungals
which may have important implications for the develop-
ment of guidelines and postgraduate continuous educa-
tion.
Material and methods
Setting
Clinical case scenarios of invasive candidiasis were presented
during planned interactive sessions at the national meetings of the
Swiss Society of Infectiology in March 2003 and the Swiss Society
of Critical Care Medicine in May 2004. These cases included
episodes of clinical sepsis related to candidemia, catheter-related
candidemia, peritonitis, isolated and complicated candiduria, and
clinical suspicion of ventilator-associated pneumonia. Each case is
summarized in the corresponding paragraph of the results section.
Participants
Study participants included 65 infectious disease specialists and 51
critical care specialists who attended the interactive sessions. None
attended both sessions. Critical care and infectious disease spe-
cialists directly involved in patient care worked in teaching hos-
pitals (43.2% vs. 50%, respectively), university-affiliated hospitals
(21.6% vs. 15.9%), community (12.7% vs. 2.3%), and private
hospitals (1.6% vs. 15.9%). Among infectious disease specialists,
29.6% were also clinical microbiologists, and 13% were specialists
in internal medicine. Among critical care physicians, 50% reported
being board-certified in intensive care medicine, 15.9% in anes-
thesiology, 15.9% in internal medicine, 9.1% in pediatrics, and
2.3% in surgery. Participants worked in mixed (54.4%), medical
(14.6%), surgical (12.3%), or pediatric (8.3%) intensive care units.
Methods
Participants gave their opinion by answering a series of questions
using an anonymous electronic voting system. Response distribu-
tion was automatically recorded. In brief, participants were first
asked to choose one of several therapeutic options for the man-
agement of patients with bloodstream infection due to Candida
albicans, C. glabrata, and C. krusei. Various options for the
management of the central venous access were then proposed.
Participants’ opinions regarding the possible pathogenicity of
Candida spp. isolated from clinical specimens were similarly
recorded. The additional cases presented concerned peritonitis from
bowel perforation and tertiary peritonitis, simple and complicated
candiduria, and a clinical condition with suspicion of ventilator-
associated pneumonia.
Statistics
To avoid a multiple testing effect in small groups, Fisher’s exact
test was used to test responses with clinically relevant differences
(more than 25%) between infectious disease and critical care spe-
cialists.
Results
Candidemia
– Case presentation: A 78-year-old diabetic man pre-
sented with abdominal pain. He underwent emergency
surgery for sigmoid perforation due to obstructive
colon cancer. On day 5 antimicrobial therapy was
broadened from amoxicillin/clavulanate to a combi-
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nation of cefepime and metronidazole because of
persistent low-grade fever (37.5C). On day 9 the pa-
tient was admitted to the ICU with acute heart failure
and pulmonary edema requiring noninvasive ventila-
tion. On day 13 meropenem was empirically started for
a new episode of clinical sepsis with suspicion of no-
socomial pneumonia; Candida spp. grew from blood
cultures.
Therapeutic options for C. albicans, C. glabrata, and
C. krusei candidemia among infectious disease and criti-
cal care specialists are shown in Table 1. Two-thirds of
specialists in both groups proposed to treat C. albicans
candidemia using fluconazole. In contrast, fluconazole
was chosen by fewer than 5% in both groups for nonal-
bicans Candida strains. Critical care physicians were
more likely than infectious disease specialists to seek the
opinion of a colleague specialized in the management of
patients with fungal infections, in particular for the
treatment of C. glabrata and C. krusei candidemia. In-
fectious disease specialists reported choosing amphoteri-
cin B or newly licensed antifungal agents (voriconazole or
caspofungin) more frequently for C. krusei infection.
Catheter-associated candidemia
– Case presentation: (The following information was
added to the above-mentioned clinical scenario.) A
central venous access in the left subclavian vein was
used for parenteral nutrition since day 1.
The management options retained for such an episode
of candidemia associated with a central venous line are
shown in Table 2. Most participants reported that they
would change or remove the line. As many as 77.1% of
critical care specialists would start concomitant antifun-
gals, compared to only 50% of infectious disease spe-
cialists (p<0.001).
Intra-abdominal infection
– Case presentation: A 75-year-old patient presented
with abdominal pain. Emergency surgery with surgical
drainage of the peritonitis and left colon resection was
performed for perforated diverticulitis. On day 3 the
patient was subfebrile (37.9C) but remained stable.
Peritoneal fluid cultures obtained during surgery grew
Escherichia coli and Proteus mirabilis in moderate
amount (++) and C. albicans in low amount (+).
Table 1 Therapeutic options
for the treatment of candidemia
Infectious disease
specialists
Critical care
specialists
Total
n % n % n %
C. albicans 63 – 47 – 110 –
Fluconazole 42 66.7 32 68.1 74 67.3
Amphotericin B 6 9.5 7 14.9 13 11.8
Other antifungalsa 5 7.9 1 2.1 6 5.5
No treatment 4 6.4 1 2.1 5 4.5
I don’t know, I would seek advice 6 9.5 6* 12.8 12 10.9
C. glabrata 58 – 41 – 99 –
Fluconazole 3 5.2 2 4.9 5 5.0
Amphotericin B 33 56.9 17 41.5 50 50.5
Other antifungalsb 20 34.5 14 34.2 34 34.3
No treatment 0 – 0 – 0 –
I don’t know, I would seek advice 2 3.5 8** 19.5 10 10.1
C. krusei 60 – 44 – 104 –
Fluconazole 0 – 1 2.3 1 0.9
Amphotericin B 34 56.6 16*** 36.4 50 48.1
Other antifungalsc 24 40.0 11 25.0 35 33.6
No treatment 0 – 0 – 0 –
I don’t know, I would seek advice 2 3.3 164* 36.4 18 17.3
* p=0.076, ** p=0.015, *** p=0.049, 4* p<0.0001 infectious disease vs. critical care specialists
(Fisher’s exact test)
a Caspofungin in 2 (3.2%) vs. 0, voriconazole in 1 (1.6%) vs. 1 (2.1%), and combined treatment in 2
(3.2%) vs. 0 among infectious disease and critical care specialists, respectively
b Caspofungin in 9 (15.5%) vs. 9 (22.0%), voriconazole in 8 (13.8%) vs. 5 (12.2%) and combined
treatment in 3 (5.1%) vs. 0 among infectious disease and critical care specialists, respectively
c Caspofungin in 13 (21.7%) vs. 4 (9.1%), voriconazole in 7 (11.7%) vs. 7 (15.9%) and combined
treatment in 4 (6.7%) vs. 0 among infectious disease specialists and critical care specialists, respec-
tively
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As shown in Table 3, C. albicans isolated during initial
surgery for peritonitis was considered as a colonizing
organism by a majority of physicians in both groups
(66.6% vs. 52.7%). However, a higher proportion of
critical care specialists would start antifungal prophylaxis
(22.2% vs. 7.2%; p=0.04). Overall, antifungal treatment
(whether considered prophylaxis or therapy) would be
prescribed by more than 50% of specialists in both
groups.
– Case presentation: Ovarectomy was performed in a
65-year-old woman with adenocarcinoma. On day 4
she required revision laparatomy with resection of a
perforated ileal section and end-to-end anastomosis.
She received meropenem and mixed bacterial flora
grew from the intraperitoneal swabs. After initial im-
provement, fever and clinical signs of peritonitis re-
lapsed on day 7. Because of the lack of clinical im-
provement and onset of organ dysfunction, abdominal
computed tomography was performed and showed
diffuse peritonitis without abscess. Microbiological
sampling performed at time of computed tomography
recovered low amounts (+) of coagulase-negative sta-
phylococci and Enterococcus faecium, both resistant to
meropenem, and C. albicans in large amounts (+++)
grew from ascitis.
The great majority of infectious disease and critical
care specialists considered C. albicans as a pathogen
during the course of tertiary peritonitis (Table 3). Most
physicians from both groups recommended using flu-
conazole as a therapeutic option for C. albicans infection.
However, 10.8% of critical care specialists would select
amphotericin B, compared to 1.8% of infectious disease
physicians only (p=0.007).
Urinary tract infection
– Case presentation: A 75-year-old woman underwent
total hip prosthesis. Intravenous line and urinary
catheter were removed on day 2. She developed fever
(38.5C) on day 7 without clinical focus of infection.
Routine microscopic urine examination showed 10–20
leukocytes per low power field and culture grew C.
albicans (104 cfu/ml).
Table 2 Management options for the treatment of catheter-associated candidemia
Infectious disease specialists (n=52) Critical care specialists (n=48) Total (n=100)
n % n % n %
Nothing 3 5.8 1 2.1 4 4.0
Change or remove without antifungalsa 21 40.4 10 20.8 31 31.0
Change or remove with antifungalsb 26 50.0 37* 77.1 63 63.0
I don’t know, I would seek advice 2 3.9 0 – 2 2.0
* p<0.0001 infectious disease vs. critical care specialists (Fisher’s exact test)
a Including change over a guidewire in 2 (3.8%) vs. 0 and removal with insertion of a new catheter at another site in 19 (36.5%) vs. 10
(20.8%) among infectious disease and critical care specialists, respectively
b Including change over a guidewire in 2 (3.8%) vs. 6 (12.5%) and removal with insertion of a new catheter at another site in 24 (46.1%)
vs. 31 (64.6%) among infectious disease and critical care specialists, respectively (p<0.0001, by Fisher’s exact test)
Table 3 Management options for Candida spp. peritonitis
Infectious disease specialists Critical care specialists Total
n % n % n %
Bowel perforation 55 – 45 – 100 –
Colonizing organism, no treatment 25 45.5 20 44.4 45 45.0
Colonizing organism, I start prophylaxis 4 7.2 10* 22.2 14 14.0
Pathogen, I start antifungalsa 25 45.5 13 28.9 38 38.0
I don’t know, I would seek advice 1 1.8 2 4.4 3 3.0
Tertiary peritonitis 58 – 37 – 95 –
Colonizing organism, no treatment 2 3.5 3 8.1 5 5.3
Colonizing organism, I start prophylaxis 1 1.7 0 – 1 1.0
Pathogen, I start antifungalsb 53 91.4 34 91.9 87 91.6
I don’t know, I would seek advice 2 3.5 0 – 2 2.1
* p=0.04 infectious disease vs. critical care specialists (Fisher’s exact test)
a Fluconazole in 23 (41.8%) vs. 13 (28.9%), amphotericin B in 2 (3.6%) vs. 0, caspofungin in 0 vs. 0, and voriconazole 0 vs. 0 among
infectious disease and critical care specialists, respectively
b Fluconazole in 50 (86.2%) vs. 29 (78.4%), amphotericin B in 1 (1.8%) vs. 4 (10.8%) (p=0.007), caspofungin in 2 (3.4%) vs. 0, and
voriconazole 0 vs. 1 (2.7%) among disease and critical care specialists, respectively
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– Case presentation: A 30-year-old man was admitted to
the ICU for multiple trauma requiring mechanical
ventilation. Initial amoxicillin/clavulanate given em-
pirically on admission for fever of unknown origin was
stopped after 3 days. On day 10, low-grade fever
(38.0–38.5C) persisted without clinical focus of in-
fection. Blood cultures were sterile and urine culture
obtained through the urinary catheter used from day 1
grew C. albicans (105 cfu/ml). Candida spp. were not
isolated from any other body site.
As shown in Table 4, approx. one-third of infectious
disease and critical care specialists considered Candida
spp. candiduria as a true fungal infection in both simple
and complicated conditions.
Respiratory tract infection
– Case presentation: A 30-year-old man was admitted to
the ICU for multiple trauma requiring mechanical
ventilation. Initial amoxicillin/clavulanate given em-
pirically for fever of unknown origin was stopped after
3 days. Fever (39.0C) developed on day 14 with bi-
lateral pulmonary infiltrates. Bronchoalveolar lavage
was performed and grew Pseudomonas aeruginosa
(102 cfu/ml), Acinetobacter baumani (102 cfu/ml), and
C. albicans (104 cfu/ml). Candida spp. were not iso-
lated from any other body site. Blood cultures re-
mained negative.
Candida spp. counts of 104 cfu/ml recovered from a
bronchoalveolar lavage performed in this patient with
clinical suspicion of ventilator-associated pneumonia
were considered as a colonizing organism by 94.9% of
infectious disease specialists, compared to 46.8% of
critical care specialists (p<0.0001; Table 5). Antifun-
gals would have been prescribed by 5.1% of infectious
disease specialists, compared to 51% of critical care
specialists (p<0.001).
Discussion
Delay or absence of antifungal therapy is associated with
poor outcome from invasive candidiasis [1, 2, 3, 4, 5].
Both intensive care and infectious disease specialists are
confronted with such critical conditions. To our knowl-
edge, this is the first report comparing the clinical man-
agement and therapeutic options for invasive candidiasis
Table 4 Management options for Candida spp. candiduria
Infectious disease specialists Critical care specialists Total
n % n % n %
Isolated candiduria 60 – 51 – 111 –
Colonizing organism, no treatment 33 55.0 31 60.8 64 57.6
Colonizing organism, I start prophylaxis 0 – 3* 5.9 3 2.7
Pathogen, I start antifungalsa 23 38.3 17 33.3 40 36.0
I don’t know, I would seek advice 4 6.7 0 – 4 3.6
Complicated candiduria 61 – 45 – 106 –
Colonizing organism, no treatment 32 52.5 27 60.0 59 55.7
Colonizing organism, I start prophylaxis 4 6.6 3 6.7 7 6.6
Pathogen, I start antifungalsb 23 37.7 14 31.1 37 34.9
I don’t know, I would seek advice 2 3.3 1 2.2 3 2.8
* p=0.09 infectious disease vs critical care specialists (Fisher’s exact test)
a Fluconazole in 17 (28.3%) vs. 16 (31.4%), amphotericin B in 4 (6.7%) vs.1 (1.9%), caspofungin in 1 (1.7%) vs. 0, and voriconazole 1
(1.7%) vs. 0 among infectious disease critical care specialists, respectively
b Including fluconazole in 21 (34.4%) vs. 13 (28.9%), amphotericin B in 0 vs. 1 (2.2%), caspofungin in 0 vs. 0, and voriconazole 2 (3.4%)
vs. 0 among infectious disease and critical care specialists, respectively
Table 5 Management options for clinical suspicion of ventilator-associated pneumonia
Infectious disease specialists (n=39) Critical care specialists (n=47) Total (n=86)
n % n % n %
Colonizing organism, no treatment 37 94.9 22* 46.8 59 68.6
Colonizing organism, I start prophylaxis 0 – 1 2.1 1 1.2
Pathogen, I start antifungalsa 2 5.1 23** 48.9 25 29.1
I don’t know, I would seek advice 0 – 1 2.1 1 1.2
* p<0.0001, ** p<0.001 infectious disease vs. critical care specialists (Fisher’s exact test)
a Fluconazole in 1 (2.6%) vs. 23 (48.9%), amphotericin B in 1 (2.6%) vs. 0, caspofungin in 0 vs. 0, and voriconazole 0 vs. 0 among
infectious disease and critical care specialists, respectively (p=0.001)
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in critically ill, non-immunosuppressed patients in these
two specialty groups.
Experts and consensus conferences recommend treat-
ing all episodes of candidemia with antifungals [25, 26,
27, 28, 29]. In this study, a large majority of participants
from both groups of physicians reported to start antifungal
therapy in patients with single blood culture-positive
episodes of candidemia. Of note, a higher proportion of
critical care specialists would ask colleagues for advice in
cases of C. albicans, C. glabrata and C. krusei candide-
mia; infectious disease specialists appear to have a better
knowledge of microbiological aspects. We were surprised
by the low proportion of specialists choosing new anti-
fungals for the treatment of non-albicans Candida spp.
candidemia [30]. Importantly, at least 10 of 63 (15.9%)
infectious disease specialists either would not treat or
would seek advice from a colleague experienced in fungal
infections. This may suggest that recommendations for
the management of fungal infections should be promoted.
In a recent prospective multicenter study in 24 adult in-
tensive care units in Paris, France, the majority (78%) of
patients with documented candidemia were treated with
fluconazole, while a significant proportion (52%) re-
ceived amphotericin B [31]. In our study we did not
survey what would have been the nature of the initial
antifungal therapy given to candidemic patients by
physicians at time of awareness of blood cultures positive
for Candida spp., but before knowledge of the species’
identification.
Intravenous catheters are the leading source of can-
didemia. To date, no randomized, controlled study has
been specifically designed to assess the benefit of sys-
tematic line removal; thus management remains contro-
versial [25, 26, 27, 28, 29, 32, 33]. Data from 15 series in
which the outcome of candidemia was studied in relation
to vascular access management have been reviewed
elsewhere [34, 35]. They support the current recommen-
dation to remove all vascular accesses at time of can-
didemia, in particular for unstable, critically ill patients
[15, 25, 26, 27, 28, 29, 32]. A large majority of partici-
pants indicated that they would remove the central venous
line in a candidemic patient, but three-quarters of critical
care specialists would concomitantly start antifungals,
compared to only one-half of infectious disease special-
ists.
Candida infections following abdominal surgery are
characterized by mortality rates higher than 50% [13, 23,
36]. However, there is no consensus nor are there criteria
for the diagnosis of fungal peritonitis. Some investigators
consider the presence of Candida spp. in any abdominal
specimen as pathogenic and recommend systematic em-
pirical antifungal treatment, while others consider it as
contamination in most situations, particularly in the case
of peritonitis resulting from bowel perforation [37, 38].
There is currently no consensus about the usefulness of
empirical or prophylactic antifungal therapy except in
patients with pancreatitis or Candida spp. recovery from
tertiary peritonitis [21, 23, 36, 37, 39]. According to our
observations, although a higher proportion of critical care
specialists would initiate antifungal prophylaxis when
Candida spp. are isolated in the case of peritonitis from
bowel perforation, more than one-half of the physicians in
both groups would use antifungal treatment in such a
condition. Such a difference in strategy might be ex-
plained by the different types of patient population both
groups of specialists have been exposed to during their
respective clinical practice.
The clinical significance of candiduria is generally
unknown. It can be detected in 20–30% of critically ill
patients equipped with a urinary catheter, can remain
asymptomatic and disappear spontaneously, lead to py-
elonephritis, or manifest occasionally as a marker of
candidemia [40]. Systematic antifungal treatment of
asymptomatic candiduria may not be beneficial, and ex-
perts recommend considering risk factors and underlying
conditions before deciding upon eventual treatment [25,
26, 27, 28, 29, 41]. In the case of C. albicans candiduria,
whether complicated or not, only one-third of participants
in both groups of specialists would start antifungal ther-
apy. More than 90% of participants in both groups indi-
cated that they would use fluconazole for the treatment of
Candida spp. candiduria. The low use of other antifungals
may reflect the very low incidence of infections due to
non-albicans strains of Candida in Switzerland [12]. A
recent prospective multicenter study in 24 French inten-
sive care units reported that 25% of patients treated for
documented candiduria effectively received antifungal
therapy, mostly fluconazole [42].
Candida spp. are often isolated from the upper respi-
ratory tract of mechanically ventilated patients and they
figure regularly among the frequent pathogens responsi-
ble for nosocomial pneumonia [43]. However, Candida
spp. have a very low affinity for pneumocytes, and his-
tologically confirmed candidal pneumonia is rare; thus
the clinical significance of Candida spp. even when re-
covered from bronchoalveolar lavage or protected brush
specimen remains difficult to determine [44, 45]. The
existence of true candidal pneumonia is doubted by most
investigators, who require histological demonstration of
invasive disease [44, 46]. In addition, thresholds for
positive quantitative cultures of bronchoalveolar lavage
fluid for Candida spp. have never been evaluated and
validated. Experts repeatedly recommend considering the
recovery of Candida spp. from the respiratory tract as
colonization that does not require antifungal therapy [25,
26, 27, 29]. Surprisingly, in our survey, in contrast to the
majority of infectious disease physicians, one-half of all
critical care specialists would consider the growth of high
amounts of Candida spp. in a bronchoalveolar lavage as
pathogenic and treat accordingly. Almost all participants
of both groups indicated that they would use fluconazole
1520
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